Biocellvia flew to its American market in March 18

Biocellvia gears up for NASH
Biocellvia has begun its NASH assay development
avril 13, 2018
Biocellvia will take part to BIO18 : the 2018 BIO International Conference
Biocellvia will be at BIO18
avril 23, 2018
Show all

Biocellvia flew to its American market in March 18

Biocellvia went to the USA in order to meet its American Market (Boston and San Francisco)

Olivier JULE, CEO at Biocellvia, Yvon JULE, CSO at Biocellvia, and Emily FANG, Biocellvia’s business manager flew to the USA on Monday, March 5th. This business trip will enable Biocellvia to further increase awareness and understanding of its cutting-edge technology within the pharmaceutical sector and to meet its American market. Biocellvia brings a breakthrough innovation: its digital image analysis solutions for preclinical trials offer more accuracy and reliability, and save considerable time and energy for scientific teams. “Once our innovative technology is ready to be commercialized, we need to meet the companies that can become our customers.” For Business France, who helped the Marseille start-up launch its debut in the USA, “Biocellvia is a success story for French innovation export”. In fact, in 2017, 80% of Biocellvia’s annual revenue is derived from North America.

 AMERICAN MARKET AND SCHEDULE

This travel will be divided into two parts: first, six days in the Boston/Cambridge area and then five days in San Francisco Bay area. Biocellvia will even hold meetings with Harvard’s scientists. Biocellvia scheduled approximately 20 meetings with biotechs and big pharmas. Among them, there are companies that Biocellvia already encountered during BIO2017 in San Diego, the international convention of pharmaceutical industry. It’s the second travel of Biocellvia to the USA, after the one in 2017 for the BIO Convention. In 2018, the commercialization of Biocellvia is marked by significant milestones. This year, three new tests are being developed in addition to the three already operational. In fact, Biocellvia developed the first assays for respiratory diseases (idiopathic pulmonary fibrosis, COPD). In 2018, Biocellvia has begun to work on NASH and its oncology programs. The next step is dedicated to neuro-degenerative diseases. Biocellvia chooses the pathologies to fulfil the ambitious target of unmet medical needs.

2018 is an important and pivotal year and this business trip kicks off this global project. Biocellvia will meet both its customers and potential prospects. This objective is for Biocellvia to demonstrate its impressive technology to the pharmaceutical companies, and to strength its ties and credibility within the sector.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *